Page last updated: 2024-10-16

carbon monoxide and Diffuse Parenchymal Lung Disease

carbon monoxide has been researched along with Diffuse Parenchymal Lung Disease in 80 studies

Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)
carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.

Research Excerpts

ExcerptRelevanceReference
" The potential of CO-releasing molecules (CORMs), substances that release CO (Carbon monoxide) within animal tissues, for treating paraquat-induced ROS generation and inflammation is investigated here."8.02The effects of carbon monoxide releasing molecules on paraquat-induced pulmonary interstitial inflammation and fibrosis. ( Chang, CY; Cheng, CH; Chiu, HY; Chuu, JJ; Huang, KC; Li, JC; Lin, LS; Wang, SM; Yeh, CH, 2021)
"There was increased mortality in interstitial lung disease‒PH as compared with chronic obstructive pulmonary disease‒PH, but PH severity based on the WHO classification did not alter survival."5.51Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide. ( Archer, SL; Misialek, JR; Prins, KW; Pritzker, M; Rose, L; Thenappan, T; Weir, EK, 2019)
" The potential of CO-releasing molecules (CORMs), substances that release CO (Carbon monoxide) within animal tissues, for treating paraquat-induced ROS generation and inflammation is investigated here."4.02The effects of carbon monoxide releasing molecules on paraquat-induced pulmonary interstitial inflammation and fibrosis. ( Chang, CY; Cheng, CH; Chiu, HY; Chuu, JJ; Huang, KC; Li, JC; Lin, LS; Wang, SM; Yeh, CH, 2021)
"1% during follow-up, and it was significantly associated to digital ulcers, interstitial lung disease, reduction of diffusion lung of carbon monoxide <75%, teleangectasias and melanodermia, while sicca syndrome and arthralgias were associated to normal/nonspecific pattern."3.81Prevalence and evolution of scleroderma pattern at nailfold videocapillaroscopy in systemic sclerosis patients: Clinical and prognostic implications. ( Campomori, F; Colaci, M; Ferri, C; Ghizzoni, C; Giuggioli, D; Manfredi, A; Sebastiani, M, 2015)
"In systemic sclerosis (SSc), impaired diffusing capacity for carbon monoxide (DLCO) can indicate interstitial lung disease (ILD), pulmonary hypertension (PH), and/or other disease manifestations, including anemia."3.79Comparison of different measures of diffusing capacity for carbon monoxide (DLCO) in systemic sclerosis. ( Assayag, D; Baron, M; Caron, M; Fox, BD; Gaudreau-Taillefer, R; Hirsch, A; Hudson, M; Rudski, L; Steele, R; Tatibouet, S, 2013)
"Diffusion capacity for carbon monoxide of the lung (DLCO) before-and-after exercise test and 5 routine pulmonary function tests were conducted in 16 patients with diffuse pulmonary fibrosis (DPF), 19 patients with interstitial pneumonia (IP), 17 patients with COPD, and 22 normal subjects."3.69[Diagnostic value of exercise diffusion capacity test on diffuse pulmonary fibrosis]. ( He, T; Luo, Y; Yuan, Y; Zeng, J, 1996)
"Extent of systemic sclerosis (SSc)-related interstitial lung disease (ILD) assessed from thoracic high-resolution CT (HRCT) predicts disease course, mortality and treatment response."2.82Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. ( Clements, P; Elashoff, R; Furst, D; Goldin, J; Khanna, D; Kim, HJ; Kleerup, E; Roth, MD; Tashkin, DP; Tseng, CH; Volkmann, ER, 2016)
"Currently, therapy for interstitial lung disease in patients with systemic sclerosis is unsatisfactory."2.74High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study. ( Bambery, P; Sharma, A; Sharma, S; Suryanaryana, BS; Wanchu, A, 2009)
"Interstitial lung disease is a rare manifestation of NPD."2.41Pulmonary involvement in Niemann-Pick disease: case report and literature review. ( Minai, OA; Stoller, JK; Sullivan, EJ, 2000)
"Pulmonary function changes in interstitial lung disease are characterized by loss of lung volume, increase in ratio of forced expiratory volume in 1 second to forced vital capacity, and decrease in carbon monoxide diffusion capacity."2.39Pulmonary physiology in interstitial lung disease: recent developments in diagnostic and prognostic implications. ( Baydur, A, 1996)
"Of the entire cohort (n = 243), systemic sclerosis (SSc)-associated ILD (n = 88, 36%), interstitial pneumonia with autoimmune features (IPAF, n = 56, 23%), rheumatoid arthritis (RA)-associated ILD (n = 42, 17%), and idiopathic inflammatory myopathy (IIM)-associated ILD (n = 26, 11%) were the most common phenotypes."1.51Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience. ( Chartrand, S; Fischer, A; Lee, JS; Stanchev, L; Swigris, JJ, 2019)
"There was increased mortality in interstitial lung disease‒PH as compared with chronic obstructive pulmonary disease‒PH, but PH severity based on the WHO classification did not alter survival."1.51Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide. ( Archer, SL; Misialek, JR; Prins, KW; Pritzker, M; Rose, L; Thenappan, T; Weir, EK, 2019)
"This study aimed to investigate the disease progression and mortality of patients with CTD-ILD and idiopathic interstitial pneumonias (IIP) including idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia and the prognostic impact of the radiological UIP pattern on both disease groups."1.51Comparison of clinical courses and mortality of connective tissue disease-associated interstitial pneumonias and chronic fibrosing idiopathic interstitial pneumonias. ( Bitik, B; Erbaş, G; Haznedaroğlu, Ş; Köktürk, N; Türk, M; Türktaş, H; Yıldırım, F, 2019)
"Pulmonary emphysema combined with systemic sclerosis (SSc)-associated interstitial lung disease (ILD) occurs more often in smokers but also in never-smokers."1.48Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy? ( Baba, T; Ikeda, S; Iso, S; Iwasawa, T; Kitamura, H; Kuwano, K; Ogura, T; Okudela, K; Sekine, A; Takemura, T; Yamakawa, H; Yamanaka, Y, 2018)
"Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is associated with significant morbidity and mortality."1.46The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease. ( Cerri, S; Collard, HR; Elicker, BM; Gross, AJ; Hu, X; Jones, KD; Kim, DS; King, TE; Lee, BY; Lee, JS; Ley, B; Manfredi, A; Morisset, J; Ryu, JH; Sebastiani, M; Tonelli, R; Vittinghoff, E; Wolters, PJ, 2017)
"Systemic sclerosis-related interstitial lung disease (SSc-ILD) is the leading cause of death in SSc."1.46Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease. ( Béhal, H; Duhamel, A; Faivre, JB; Hachulla, AL; Hachulla, E; Hatron, PY; Lambert, M; Launay, D; Le Gouellec, N; Matran, R; Morell-Dubois, S; Perez, T; Remy-Jardin, M; Sobanski, V, 2017)
"Unclassifiable-interstitial lung disease (uILD) represents a heterogeneous collection of pathologies encompassing those fibrosing lung diseases which do not fulfill current diagnostic criteria."1.46Unclassifiable-interstitial lung disease: Outcome prediction using CT and functional indices. ( Bartholmai, BJ; Brun, AL; Egashira, R; Hansell, DM; Jacob, J; Karwoski, R; Kokosi, M; Nair, A; Nicholson, AG; Rajagopalan, S; Walsh, SLF; Wells, AU, 2017)
"The test time of re-breathing in the COPD group (106 ± 5) s was significant longer than that of the ILD group (73 ± 4) s and the control group (79 ± 5) s (F = 11."1.39[Single-breath and rebreathing methods for measurement of pulmonary diffusing function: a comparative study]. ( An, JY; Gao, Y; Guan, WJ; Jiang, CY; Liu, QX; Liu, WT; Xie, YQ; Yu, XX; Zheng, JP, 2013)
"TwPmo and TwPdi were lower in interstitial lung disease patients (mean±sd TwPmo 0."1.39Respiratory muscle function in interstitial lung disease. ( Kabitz, HJ; Müller-Quernheim, J; Schlager, D; Walker, DJ; Walterspacher, S; Windisch, W, 2013)
"In very severe interstitial lung disease associated with connective tissue disease (CTD-ILD), progressing despite maximal conventional immunosuppression, there is no effective medical rescue therapy."1.38Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. ( Denton, CP; Hansell, DM; Keir, GJ; Maher, TM; Ong, VH; Renzoni, EA; Singh, S; Wells, AU, 2012)
"More than 80% of patients with systemic sclerosis (SSc) develop lung involvement, most commonly interstitial pneumonia (IP)."1.38The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis. ( Carns, M; Fingerlin, TE; Hinchcliff, ME; Murphy, E; Peljto, AL; Podlusky, S; Schwartz, DA; Schwarz, M; Steele, MP; Varga, J, 2012)
"Pulmonary hypertension (PH) complicating systemic sclerosis (SSc)-related interstitial lung disease (ILD) is usually associated with a poor prognosis."1.37Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. ( Allanore, Y; Berezne, A; Bletry, O; Clerson, P; Cottin, V; Couderc, LJ; Hachulla, E; Hatron, PY; Humbert, M; Launay, D; Le Pavec, J; Mouthon, L; Yaici, A, 2011)
"Different interstitial lung diseases may show distinct lymphocyte activation profiles."1.36T-cell activation profiles in different granulomatous interstitial lung diseases--a role for CD8+CD28(null) cells? ( Claessen, AM; Grutters, JC; Heron, M; van den Bosch, JM, 2010)
"Sarcoidosis is a systemic granulomatous disease with predominant manifestation in the lungs, often presenting as interstitial lung disease."1.36Impaired lung compliance and DL,CO but no restrictive ventilatory defect in sarcoidosis. ( Boros, PW; Borsboom, GJ; Enright, PL; Hyatt, RE; Quanjer, PH; Wesolowski, SP, 2010)
"Pulmonary fibrosis is defined by an overgrowth of fibroblasts and extracellular matrix deposition, and results in respiratory dysfunction that is often fatal."1.36MRP14 is elevated in the bronchoalveolar lavage fluid of fibrosing interstitial lung diseases. ( Grutters, JC; Kazemier, KM; Korthagen, NM; Nagtegaal, MM; van den Bosch, JM; van Moorsel, CH, 2010)
"Among the most common are interstitial lung disease (ILD) and bronchiectasis."1.35Clinical and high resolution computed tomography characteristics of patients with rheumatoid arthritis lung disease. ( Abdul Manap, R; Azhar Shah, S; Mohd Noor, N; Mohd Shahrir, MS; Shahid, MS; Shahizon Azura, AM, 2009)
"The 14 patients without emphysema had interstitial lung disease, pulmonary vascular disease, and other isolated findings."1.34Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: implications for the diagnosis of combined obstructive and restrictive lung disease. ( Aduen, JF; Alvarez, F; Biewend, M; Jolles, HI; Keller, CA; Mobin, SI; Venegas, C; Zisman, DA, 2007)
"Age and the presence of interstitial lung disease (ILD) were associated with more frequent occurrence of TG > 23 and > 33 mmHg initially and at follow-up, but were not associated with progression rate."1.33Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001. ( Akesson, A; Ekman, R; Eskilsson, J; Hesselstrand, R; Isaksson, A; Ohlin, AK; Scheja, A, 2005)
"Diffuse parenchymal lung disease is associated with a high risk of mortality despite early referral and listing for lung transplantation."1.33Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation. ( Arcasoy, SM; Bartels, MN; Kawut, SM; O'Shea, MK; Sonett, JR; Wilt, JS, 2005)
" In three patients the pulmonary disorder seems to have been caused by a cell-mediated immunological side effect in the form of interstitial pneumonitis."1.32Pulmonary side effects of interferon-alpha therapy in patients with hematological malignancies. ( Anderson, P; Höglund, M; Rödjer, S, 2003)
"Amiodarone is a useful drug for the treatment of life-threatening cardiac arrhythmias."1.31Serum KL-6 as a possible marker for amiodarone-induced pulmonary toxicity. ( Kawahara, Y; Matsushima, T; Miyashita, N; Nakajima, M; Niki, Y; Yoshida, K, 2000)

Research

Studies (80)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (3.75)18.2507
2000's21 (26.25)29.6817
2010's44 (55.00)24.3611
2020's12 (15.00)2.80

Authors

AuthorsStudies
Zhang, K1
Zou, X1
Ma, Z1
Liu, X1
Qiu, C1
Xie, L1
Lin, Z1
Li, S1
Wu, Y1
Ibrahim, NH1
Fawzy, IM1
Gouda, TM1
El Sayed, RAH1
Morsi, MH1
Sabry, ASM1
Hashaad, NI1
Şenkal, N1
Kıyan, E1
Demir, AA1
Yalçınkaya, Y1
Gül, A1
İnanç, M1
Öçal, ML1
Esen, BA1
Axtell, AL1
David, EA1
Block, MI1
Parsons, N1
Habib, R1
Muniappan, A1
Taytard, J1
Boizeau, P1
Alberti, C1
Beydon, N1
Chartrand, S2
Lee, JS4
Swigris, JJ3
Stanchev, L2
Fischer, A3
Ciaffi, J1
van Leeuwen, NM1
Liem, SIE1
Ninaber, MK1
Huizinga, TWJ1
de Vries-Bouwstra, JK1
Distler, O1
Assassi, S1
Cottin, V2
Cutolo, M1
Danoff, SK1
Denton, CP2
Distler, JHW2
Hoffmann-Vold, AM1
Johnson, SR1
Müller Ladner, U1
Smith, V1
Volkmann, ER3
Maher, TM2
Sekine, A2
Wasamoto, S1
Hagiwara, E1
Yamakawa, H2
Ikeda, S2
Okabayashi, H1
Oda, T1
Okuda, R1
Kitamura, H2
Baba, T2
Komatsu, S1
Ogura, T2
Shen, YW1
Zhang, YM1
Huang, ZG1
Wang, GC1
Peng, QL1
Štorkánová, H1
Oreská, S1
Špiritović, M1
Heřmánková, B1
Bubová, K1
Komarc, M1
Pavelka, K1
Vencovský, J1
Šenolt, L1
Bečvář, R1
Tomčík, M1
Wardyn, PM1
de Broucker, V1
Chenivesse, C1
Sobaszek, A1
Van Bulck, R1
Perez, T3
Edmé, JL1
Hulo, S1
Huang, KC1
Li, JC1
Wang, SM1
Cheng, CH1
Yeh, CH1
Lin, LS1
Chiu, HY1
Chang, CY1
Chuu, JJ1
Pitsidianakis, G1
Vassalou, EE1
Vasarmidi, E1
Bolaki, M1
Klontzas, ME1
Xirouchaki, N1
Georgopoulos, D1
Karantanas, AH1
Tzanakis, N1
Antoniou, KM1
Layton, AM1
Armstrong, HF1
Kim, HP1
Meza, KS1
D'Ovidio, F1
Arcasoy, SM2
Natalini, JG1
Morisset, J2
Elicker, BM2
Jones, KD2
Collard, HR2
Vittinghoff, E1
Lee, BY1
Tonelli, R1
Hu, X1
Ryu, JH1
Cerri, S2
Manfredi, A3
Sebastiani, M3
Gross, AJ1
Ley, B1
Wolters, PJ1
King, TE1
Kim, DS1
Ungprasert, P1
Wilton, KM1
Ernste, FC1
Kalra, S1
Crowson, CS1
Rajagopalan, S2
Bartholmai, BJ3
Arcadu, A1
Byrne, SC1
Pirina, P1
Hartman, TE1
Moua, T1
Le Gouellec, N1
Duhamel, A1
Hachulla, AL1
Sobanski, V2
Faivre, JB1
Morell-Dubois, S3
Lambert, M3
Hatron, PY4
Hachulla, E4
Béhal, H1
Matran, R2
Launay, D4
Remy-Jardin, M3
Du Plessis, JP1
Fernandes, S1
Jamal, R1
Camp, P1
Johannson, K1
Schaeffer, M1
Wilcox, PG1
Guenette, JA1
Ryerson, CJ1
Jacob, J1
Egashira, R1
Brun, AL1
Kokosi, M1
Nair, A1
Walsh, SLF1
Karwoski, R1
Nicholson, AG1
Hansell, DM2
Wells, AU2
Hashimoto, N1
Ando, A1
Iwano, S1
Sakamoto, K1
Okachi, S1
Matsuzaki, A1
Okada, Y1
Wakai, K1
Yokoi, K1
Hasegawa, Y1
Takemura, T1
Iwasawa, T1
Yamanaka, Y1
Iso, S1
Okudela, K1
Kuwano, K1
Barratt, SL1
Shaw, J1
Jones, R1
Bibby, A1
Adamali, H1
Mustfa, N1
Cliff, I1
Stone, H1
Chaudhuri, N1
Caetano, J1
Paula, FS1
Amaral, M1
Oliveira, S1
Alves, JD1
Öztürk, A1
Kayacan, O1
Rose, L1
Prins, KW1
Archer, SL1
Pritzker, M1
Weir, EK1
Misialek, JR1
Thenappan, T1
Tashkin, DP2
Sim, M1
Li, N1
Goldmuntz, E1
Keyes-Elstein, L1
Pinckney, A1
Furst, DE1
Clements, PJ1
Khanna, D2
Steen, V1
Schraufnagel, DE1
Arami, S1
Hsu, V1
Roth, MD2
Elashoff, RM1
Sullivan, KM1
Yıldırım, F1
Türk, M1
Bitik, B1
Erbaş, G1
Köktürk, N1
Haznedaroğlu, Ş1
Türktaş, H1
Ghang, B1
Lee, J1
Chan Kwon, O1
Ahn, SM1
Oh, JS1
Hong, S1
Kim, YG1
Yoo, B1
Jeong, WS1
Kim, J1
Lee, CK1
Hudson, M1
Assayag, D1
Caron, M1
Fox, BD1
Hirsch, A1
Steele, R1
Gaudreau-Taillefer, R1
Tatibouet, S1
Rudski, L1
Baron, M1
Someya, F1
Mugii, N1
Hasegawa, M1
Yahata, T1
Nakagawa, T1
Sivova, N1
Wémeau-Stervinou, L1
De Groote, P2
Denis, G1
Lamblin, N1
Fertin, M1
Lefevre, G1
Le Rouzic, O1
Wallaert, B1
Liu, QX1
Zheng, JP1
Xie, YQ1
Guan, WJ1
Jiang, CY1
An, JY1
Yu, XX1
Liu, WT1
Gao, Y1
Tseng, CH1
Kim, HJ1
Goldin, J1
Clements, P1
Furst, D1
Kleerup, E1
Elashoff, R1
Ghizzoni, C1
Campomori, F1
Colaci, M2
Giuggioli, D2
Ferri, C2
Pastre, J1
Plantier, L1
Planes, C1
Borie, R1
Nunes, H1
Delclaux, C1
Israël-Biet, D1
Legnani, D1
Rizzi, M1
Sarzi-Puttini, P1
Cristiano, A1
La Spina, T1
Frassanito, F1
Airoldi, A1
Atzeni, F1
Go, DJ1
Lee, EY1
Lee, EB1
Song, YW1
Konig, MF1
Park, JK1
Lumetti, F1
Luppi, F1
Enright Md, P1
Pingel, S1
Passon, SG1
Pausewang, KS1
Blatzheim, AK1
Pizarro, C1
Tuleta, I1
Gliem, M1
Charbel Issa, P1
Schahab, N1
Nickenig, G1
Skowasch, D1
Schaefer, CA1
Brown, KK1
Callahan, SJ1
Xia, M1
Murray, S1
Flaherty, KR1
Shin, KM1
Lee, KS1
Chung, MP1
Han, J1
Bae, YA1
Kim, TS1
Chung, MJ1
Hegewald, MJ1
Heron, M1
Claessen, AM1
Grutters, JC3
van den Bosch, JM2
Funauchi, M1
Kishimoto, K1
Kinoshita, K1
Mohd Noor, N1
Mohd Shahrir, MS1
Shahid, MS1
Abdul Manap, R1
Shahizon Azura, AM1
Azhar Shah, S1
Wanchu, A1
Suryanaryana, BS1
Sharma, S1
Sharma, A1
Bambery, P1
Boros, PW1
Enright, PL2
Quanjer, PH1
Borsboom, GJ1
Wesolowski, SP1
Hyatt, RE1
Korthagen, NM1
Nagtegaal, MM1
van Moorsel, CH1
Kazemier, KM1
Humbert, M1
Berezne, A1
Allanore, Y1
Couderc, LJ1
Bletry, O1
Yaici, A1
Mouthon, L3
Le Pavec, J1
Clerson, P1
Trad, S1
Huong, du LT1
Frances, C1
Wechsler, B1
Cacoub, P1
Costedoat, N1
Haroche, J1
Piette, JC1
Hanslik, T1
Amoura, Z1
Aozasa, N1
Asano, Y1
Akamata, K1
Noda, S1
Masui, Y1
Tamaki, Z1
Tada, Y1
Sugaya, M1
Kadono, T1
Sato, S1
Keir, GJ1
Ong, VH1
Singh, S1
Renzoni, EA1
Pernot, J1
Puzenat, E1
Magy-Bertrand, N1
Manzoni, P1
Gondouin, A1
Bourdin, H1
Simon-Rigaud, ML1
Regnard, J1
Degano, B1
Peljto, AL1
Steele, MP1
Fingerlin, TE1
Hinchcliff, ME1
Murphy, E1
Podlusky, S1
Carns, M1
Schwarz, M1
Varga, J1
Schwartz, DA1
Walterspacher, S1
Schlager, D1
Walker, DJ1
Müller-Quernheim, J1
Windisch, W1
Kabitz, HJ1
Ehsan, Z1
Montgomery, GS1
Tiller, C1
Kisling, J1
Chang, DV1
Tepper, RS1
Christensen, CC1
Ryg, MS1
Refvem, OK1
Skjønsberg, OH1
Zheng, J1
Pan, M1
Ding, X1
Deng, W1
Anderson, P1
Höglund, M1
Rödjer, S1
Miller, A1
Brown, LK1
Pastores, GM1
Desnick, RJ1
Yoshioka, Y1
Saiki, S1
Tsutsumi-Ishii, Y1
Koyama, R1
Hirashima, N1
Harada, N1
Yamasaki, S1
Suda, K1
Fukuchi, Y1
Hesselstrand, R1
Ekman, R1
Eskilsson, J1
Isaksson, A1
Scheja, A1
Ohlin, AK1
Akesson, A1
Kadota, J1
Mizunoe, S1
Mito, K1
Mukae, H1
Yoshioka, S1
Kawakami, K1
Koguchi, Y1
Fukushima, K1
Kon, S1
Kohno, S1
Saito, A1
Uede, T1
Nasu, M1
Kawut, SM1
O'Shea, MK1
Bartels, MN1
Wilt, JS1
Sonett, JR1
van der Lee, I1
Zanen, P1
Snijder, RJ1
van den Bosch, JMM1
Aduen, JF1
Zisman, DA1
Mobin, SI1
Venegas, C1
Alvarez, F1
Biewend, M1
Jolles, HI1
Keller, CA1
Tiev, KP1
Cabane, J1
Aubourg, F1
Kettaneh, A1
Ziani, M1
Duong-Quy, S1
Fajac, I1
Guillevin, L2
Dinh-Xuan, AT1
Pagnoux, C1
Queyrel, V1
Quadrelli, S1
Ciallella, L1
Catalán Pellet, AC1
Molinari, L1
Salvado, A1
Auad, C1
Spina, JC1
Bankier, AA1
Kiener, HP1
Wiesmayr, MN1
Fleischmann, D1
Kontrus, M1
Herold, CJ1
Graninger, W1
Hübsch, P1
Baydur, A1
Yuan, Y1
Luo, Y1
Zeng, J1
He, T1
Minai, OA1
Sullivan, EJ1
Stoller, JK1
Nakajima, M1
Kawahara, Y1
Yoshida, K1
Miyashita, N1
Niki, Y1
Matsushima, T1
Hadeli, KO1
Siegel, EM1
Sherrill, DL1
Beck, KC1

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Cyclophosphamide Versus Placebo in Scleroderma Lung Study[NCT00004563]Phase 3158 participants (Actual)Interventional1999-08-31Completed
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)[NCT00883129]Phase 2142 participants (Actual)Interventional2009-09-30Completed
A Randomized, Double Blind Controlled Trial Comparing Rituximab Against Intravenous Cyclophosphamide in Connective Tissue Disease Associated Interstitial Lung Disease[NCT01862926]Phase 2/Phase 3104 participants (Actual)Interventional2014-11-30Completed
Changes in Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide After Allogeneic Versus Autologous Hematopoietic Stem-cell Transplantation[NCT01735526]40 participants (Actual)Observational2012-10-31Completed
Comparison of Upper and Lower Limb Maximal Exercise Capacities, Muscle Oxygenation and Energy Consumption During Tests in Patients With Interstitial Lung Disease[NCT06141603]30 participants (Anticipated)Observational2023-11-25Recruiting
Comparison of Different Functional Tests and Relation With Functional State and Quality of Life in Individuals With Chronic Obstructive Pulmonary Disease (COPD)[NCT00660738]11 participants (Actual)Observational2007-01-31Completed
Reproducibility of 6 Minute Walk Tests for Oxygen Desaturation[NCT00740220]97 participants (Actual)Observational2006-09-30Completed
Evaluation of Reliability, Sensitivity and Validity of the Six Minute Step Test in Patients With Chronic Obstructive Pulmonary Disease and Its Relation With Predictors Markers of Risk of Death[NCT01298661]91 participants (Actual)Interventional2011-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

DLCO

diffusing capacity of the lungs for carbon monoxide (NCT00004563)
Timeframe: 12 months

Intervention% of predicted (Mean)
Cylophosphamide42.8
Placebo44.3

Forced Vital Capacity

The primary end point was the forced vital capacity (FVC, expressed as a percentage of the predicted value) at 12 months, after adjustment for the baseline FVC. (NCT00004563)
Timeframe: 12 months

Intervention% of predicted (Mean)
Cylophosphamide66.6
Placebo65.6

Total Lung Capacity

expressed as a percentage of the predicted value (NCT00004563)
Timeframe: 12 months

Intervention% of predicted (Mean)
Cylophosphamide70.5
Placebo64.7

Fibrosis Score, as Measured by Thoracic High Resolution Computerized Tomography (HRCT)

Imaging of the whole lung (WL) is performed using a volumetric high resolution computerized tomography (HRCT) scan, which is then analyzed using a computer algorithm to determine the percentage of overall pixels exhibiting features characteristic for quantitative lung fibrosis (QLF). Higher percentages for QLF-WL therefore represent greater involvement by lung fibrosis. (NCT00883129)
Timeframe: Measured at baseline and Month 24

,
Intervention% of lung exhibiting QLF (Mean)
BaselineMonth 24
Cyclophosphamide Arm8.918.48
Mycophenolate Arm8.257.99

Forced Vital Capacity (FVC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value

The primary outcome is the course over time from baseline to 24 months for the FVC %-predicted. The FVC %-predicted represents the adjusted volume of air (adjusted as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity) that can be forcibly exhaled from the lungs after taking the deepest breath possible. The FVC %-predicted is reduced in patients with interstitial lung disease and is used as a measure of lung involvement and disease severity. (NCT00883129)
Timeframe: Measured at study Baseline and Months 3, 6, 12, 15, 18, 21, and 24

,
InterventionFVC %-pred (Mean)
BaselineMonth 3Month 6Month 9Month 12Month 15Month 18Month 21Month 24
Cyclophosphamide Arm66.5267.0367.8669.4269.8671.9472.5772.5570.15
Mycophenolate Arm66.5266.2268.0268.1168.4369.8470.5770.8769.65

Health-related Quality of Life as Measured by the Patient Responses to the Health Assessment Questionnaire Disability Index (HAQ-DI)

The HAQ-DI asks questions related to 8 activity domains (dressing, arising, eating, walking, hygiene, reach, grip, and common daily activities) with the patient's capacity to carry out each activity scored from 0 to 3. Scores across all domains are averaged and a higher score represents greater disability. (NCT00883129)
Timeframe: Measured at study entry and Months 3, 6, 9, 12, 15, 18, 21, and 24

,
InterventionHAQ-DI Total Score (Mean)
BaselineMonth 3Month 6Month 9Month 12Month 15Month 18Month 21Month 24
Cyclophosphamide Arm0.740.640.580.650.560.620.550.480.57
Mycophenolate Arm0.710.830.750.660.640.580.550.650.62

Single-breath Diffusing Capacity for Carbon Monoxide (DLCO), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value

The DLCO is a pulmonary function test that measures the capacity for the lung to carry out gas exchange between the inhaled breath and the pulmonary capillary blood vessels and the DLCO %-predicted represents the DLCO expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity. The DLCO %-predicted is reduced in patients with interstitial lung disease and is used as a measure of disease severity. (NCT00883129)
Timeframe: Measured at study entry and Months 3, 6, 12, 15, 18, 21, and 24

,
InterventionDLCO %-pred (Mean)
BaselineMonth 3Month 6Month 9Month 12Month 15Month 18Month 21Month 24
Cyclophosphamide Arm54.0551.9250.8751.5553.1253.6255.954.2652.90
Mycophenolate Arm53.9953.3854.8654.1355.3257.7756.6255.4755.31

Skin Involvement, as Measured by the Modified Rodnam Skin Thickness Scores (mRSS)

Skin thickness is quantified using the modified Rodnan measurement method (mRSS), with a scale that ranges from 0 (no skin involvement) to a maximum of 51. The reported skin score is determined by a clinical assessment of skin thickness, which is performed by a trained reader, and represents the sum of individual assessments that are made in each of 17 body areas. Each area is given a score in the range of 0-3 (0 = normal; 1= mild thickness; 2 = moderate; 3 = severe thickness). A higher score represents more severe skin involvement. (NCT00883129)
Timeframe: Measured at baseline and Months 3, 6, 9, 12, 15, 18, 21, and 24

,
InterventionmRSS score (Mean)
BaselineMonth 3Month 6Month 9Month 12Month 15Month 18Month 21Month 24
Cyclophosphamide Arm14.0412.8511.9510.619.479.809.878.507.87
Mycophenolate Arm15.3216.0314.3714.3312.4512.4311.9811.2211.40

Tolerability, as Assessed by the Time to Withdrawal From the Study Drug or Meeting Protocol-defined Criteria for Treatment Failure.

The number of participants who remained in the study at the listed time points are reported (NCT00883129)
Timeframe: Continuous assessment from randomization to 24 months

,
InterventionParticipants (Count of Participants)
BaselineMonth 3Month 6Month 9Month 12Month 15Month 18Month 21Month 24
Cyclophosphamide Arm736456514644423938
Mycophenolate Arm696658555252494949

Total Lung Capacity (TLC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value

The TLC represents the total volume of air within the lung after taking the deepest breath possible and the TLC %-predicted represents the TLC expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity. The TLC %-predicted is reduced in patients with interstitial lung disease and is used as a measure of disease severity. (NCT00883129)
Timeframe: Measured at study entry and Months 6, 12, 18, and 24

,
InterventionTLC %-pred (Mean)
BaselineMonth 6Month 12Month 18Month 24
Cyclophosphamide Arm65.4967.3968.2569.6366.97
Mycophenolate Arm66.1667.8467.3168.5068.24

Toxicity, as Measured by Adverse Events, Serious Adverse Events, and Death

(NCT00883129)
Timeframe: Measured throughout the 2-year study

,
InterventionParticipants (Count of Participants)
Leukopenia (<2.5x10^3 WBC/microliter)Neutropenia (<1.0x10^3 neutrophils/microliter)Anemia (Hgb <10 g/dl)Thrombocytopenia (<100x10^3 platelets/microliter)Hematuria (>10 RBC/high power field)PneumoniaSAE-TotalSAE-related to treatmentDeaths
Cyclophosphamide Arm3071342422711
Mycophenolate Arm4380352735

Transitional Dyspnea Index Score

Change in breathlessness was assessed using the Transitional Dyspnea Index, which compares current symptoms to those at baseline. Total score ranges from - 9 to + 9. The lower the score, the more deterioration in severity of dyspnea. (NCT00883129)
Timeframe: Measured at Months 6, 12, 18, and 24

,
InterventionTransitional Dyspnea Index Score (Mean)
Month 6Month 12Month 18Month 24
Cyclophosphamide Arm0.311.231.782.09
Mycophenolate Arm0.741.170.911.86

Kappa Statistic for Correlation of the Oxygen Saturation Across 3 Serial 6 Minute Walk Tests (6MWT)

The kappa statistic is a measure of the quality of a test. It is a ratio. (NCT00740220)
Timeframe: All three 6MWTs should take place within 30 days

InterventionRatio (Number)
Single Arm Prospective Observational Study0.62

"Body-Mass Index, Airflow Obstruction, Dyspnea, Exercise Capacity Index (BODE Index)"

"It was evaluated only in the COPD patients. BODE index is a prognostic index used in COPD patients, it is a 0-10 scale, where lower values means better prognostic. It is composed by other commonly used evaluations tools in COPD, Forced Expiratory Volume in the First second (from spirometry); classification in the scale ranging from 0-3, Body-mass index, classification in the scale ranging from 0-1; Six-minute walk test distance, classification in the scale ranging from 0-3 and referred dyspnea, classification in the scale ranging from 0-3.~It was only used the total score (0-10)" (NCT01298661)
Timeframe: Second day

Interventionunits on a scale (Median)
COPD Patients3

"First Six Minute Step Test Exertion Perception"

"This test will be conducted by the Rater 1, the patient will step up and down one 20cm step during six minute. The Exertion Perception will be evaluated using BORG scale. This scale is a self-reported scale, which range from 0 to 10, where 0 means none exertion perception and 10 means very intense exertion perception (the highest the patient has ever felt). Lower values means that the patient feel less discomfort." (NCT01298661)
Timeframe: First day or second day of the protocol (random)

Interventionunits on a scale (Median)
Healthy Young Subjects2
Healthy Elderly Subjects2.5
COPD Patients2

"First Six Minute Step Test Heart Rate"

"This test will be conducted by the Rater 1, the patient will step up and down a 20cm step during six minute. It will be evaluated by a cardio monitor." (NCT01298661)
Timeframe: First day or second day of the protocol (random)

Interventionbpm (Mean)
Healthy Young Subjects154
Healthy Elderly Subjects116
COPD Patients117

"First Six Minute Step Test Performance"

"This test will be conducted by the Rater 1, the patient will step up and down a 20cm step during six minute. The performance will be evaluated by the number of the steps." (NCT01298661)
Timeframe: First day or second day of the protocol (random)

Interventionsteps (Mean)
Healthy Young Subjects166.4
Healthy Elderly Subjects114.0
COPD Patients76.6

"First Six Minute Step Test Peripheral Oxygen Saturation"

"This test will be conducted by the Rater 1, the patient will step up and down one 20cm step during six minute. It will be evaluated by a pulse oxymeter." (NCT01298661)
Timeframe: First day or second day of the protocol (random)

Intervention% of hemoglobin (Mean)
Healthy Young Subjects95.8
Healthy Elderly Subjects95
COPD Patients90.1

"First Six Minute Walk Test Distance"

"This test will be conducted by the Rater 1, the subject will walk as far as it can in a 30m corridor during 6 minutes. The performance will be the distance (meters)that it walk." (NCT01298661)
Timeframe: First day or second day of the protocol (random)

Interventionmeter (Mean)
Healthy Young Subjects643.5
Healthy Elderly Subjects504.5
COPD Patients380.4

"First Six Minute Walk Test Exertion Perception"

"This test was conducted by the Rater 1, the subject walked as far as it could in a 30m corridor during 6 minutes. The Exertion Perception will be evaluated using BORG scale. This scale is a self-reported scale, which range from 0 to 10, where 0 means none exertion perception and 10 means very intense exertion perception (the highest the patient has ever felt). Lower values means that the patient feel less discomfort." (NCT01298661)
Timeframe: First day or second day of the protocol (random)

Interventionunits on a scale (Median)
Healthy Young Subjects1
Healthy Elderly Subjects0.5
COPD Patients1

"First Six Minute Walk Test Heart Rate"

"This test will be conducted by the Rater 1, the subject will walk as far as it can in a 30m corridor during 6 minutes. It will be evaluated by a cardio monitor." (NCT01298661)
Timeframe: First day or second day of the protocol (random)

Interventionbpm (Mean)
Healthy Young Subjects143
Healthy Elderly Subjects115
COPD Patients113

"First Six Minute Walk Test Peripheral Oxygen Saturation"

"This test will be conducted by the Rater 1, the subject will walk as far as it can in a 30m corridor during 6 minutes. It will be evaluated by a pulse oxymeter." (NCT01298661)
Timeframe: First day or second day of the protocol (random)

Intervention% of hemoglobin (Mean)
Healthy Young Subjects96.7
Healthy Elderly Subjects94.5
COPD Patients90.4

"Second Six Minute Step Test Exertion Perception"

"This test will be conducted by the Rater 1, the patient will step up and down one 20cm step during six minute.The Exertion Perception will be evaluated using BORG scale. This scale is a self-reported scale, which range from 0 to 10, where 0 means none exertion perception and 10 means very intense exertion perception (the highest the patient has ever felt). Lower values means that the patient feel less discomfort." (NCT01298661)
Timeframe: First day or second day of the protocol (random), 30 minutes after the first 6MST

Interventionunits on a scale (Median)
Healthy Young Subjects2
Healthy Elderly Subjects1.5
COPD Patients2.5

"Second Six Minute Step Test Heart Rate"

"This test will be conducted by the Rater 1, the patient will step up and down a 20cm step during six minute. It will be evaluated by a cardio monitor." (NCT01298661)
Timeframe: First day or second day of the protocol (random), 30 minutes after the first 6MST

Interventionbpm (Mean)
Healthy Young Subjects159
Healthy Elderly Subjects118
COPD Patients117

"Second Six Minute Step Test Performance"

"This test will be conducted by the Rater 1, the patient will step up and down a 20cm step during six minutes. The performance will be evaluated by the number of the climbs." (NCT01298661)
Timeframe: On the first or second day of evaluation (random), 30 minutes after the first 6MST.

Interventionsteps (Mean)
Healthy Young Subjects170.7
Healthy Elderly Subjects114.5
COPD Patients82.4

"Second Six Minute Step Test Peripheral Oxygen Saturation"

"This test will be conducted by the Rater 1, the patient will step up and down one 20cm step during six minute. It will be evaluated by a pulse oxymeter ." (NCT01298661)
Timeframe: First day or second day of the protocol (random) ,30 minutes after the first 6MST

Intervention% of hemoglobin (Mean)
Healthy Young Subjects96
Healthy Elderly Subjects94.9
COPD Patients90.5

"Second Six Minute Walk Test Distance"

"This test will be conducted by the Rater 1, the subject will walk as far as it can in a 30m corridor during 6 minutes. The performance will be the distance (meters)that it walk." (NCT01298661)
Timeframe: On the first or second day of evaluation (random), 30 minutes after the first 6MWT.

Interventionmeter (Mean)
Healthy Young Subjects648.2
Healthy Elderly Subjects513.6
COPD Patients391.0

"Second Six Minute Walk Test Exertion Perception"

"This test will be conducted by the Rater 1, the subject will walk as far as it can in a 30m corridor during 6 minutes. The Exertion Perception will be evaluated using BORG scale. This scale is a self-reported scale, which range from 0 to 10, where 0 means none exertion perception and 10 means very intense exertion perception (the highest the patient has ever felt). Lower values means that the patient feel less discomfort." (NCT01298661)
Timeframe: First day or second day of the protocol (random), 30 minutes after the first 6MWT

Interventionunits on a scale (Median)
Healthy Young Subjects0.5
Healthy Elderly Subjects0.5
COPD Patients1

"Second Six Minute Walk Test Heart Rate"

"This test will be conducted by the Rater 1, the subject will walk as far as it can in a 30m corridor during 6 minutes. It will be evaluated by a cardio monitor at rest and every two minutes of the test." (NCT01298661)
Timeframe: First day or second day of the protocol (random), 30 minutes after the first 6MWT

Interventionbpm (Mean)
Healthy Young Subjects144
Healthy Elderly Subjects115
COPD Patients112

"Second Six Minute Walk Test Peripheral Oxygen Saturation"

"This test will be conducted by the Rater 1, the subject will walk as far as it can in a 30m corridor during 6 minutes. It will be evaluated by a pulse oxymeter." (NCT01298661)
Timeframe: ,First day or second day of the protocol (random) 30 minutes after the first 6MWT

Intervention% of hemoglobin (Mean)
Healthy Young Subjects96.4
Healthy Elderly Subjects95.1
COPD Patients90.3

"Third Six Minute Step Test Exertion Perception"

"This test will be conducted by the Rater 2, the patient will step up down one 20cm step during six minute. The Exertion Perception will be evaluated using BORG scale. This scale is a self-reported scale, which range from 0 to 10, where 0 means none exertion perception and 10 means very intense exertion perception (the highest the patient has ever felt). Lower values means that the patient feel less discomfort." (NCT01298661)
Timeframe: On the third day of evaluation, seven days after the first day of evaluation. Since it was performed in the same day of the third 6MWT, the choice of the first test was random, and there was a 30 minute interval between them.

Interventionunits on a scale (Median)
Healthy Young Subjects1
Healthy Elderly Subjects2
COPD Patients2.5

"Third Six Minute Step Test Heart Rate"

"This test will be conducted by the Rater 2, the patient will step up and down a 20cm step during six minute. It will be evaluated by a cardio monitor." (NCT01298661)
Timeframe: On the third day of evaluation, seven days after the first day of evaluation. Since it was performed in the same day of the third 6MWT, the choice of the first test was random, and there was a 30 minute interval between them.

Interventionbpm (Mean)
Healthy Young Subjects156
Healthy Elderly Subjects117
COPD Patients116

"Third Six Minute Step Test Performance"

"This test will be conducted by the Rater 2, the patient will step up and down a 20cm step during six minutes. The performance will be evaluated by the number of the climbs." (NCT01298661)
Timeframe: On the third day of evaluation, seven days after the first day of evaluation. Since it was performed in the same day of the third 6MWT, the choice of the first test was random, and there was a 30 minute interval between them.

Interventionsteps (Mean)
Healthy Young Subjects172.3
Healthy Elderly Subjects111.3
COPD Patients86.4

"Third Six Minute Step Test Peripheral Oxygen Saturation"

"This test will be conducted by the Rater 2, the patient will step up and down one 20cm step during six minute. It will be evaluated by a pulse oxymeter." (NCT01298661)
Timeframe: On the third day of evaluation, seven days after the first day of evaluation. Since it was performed in the same day of the third 6MWT, the choice of the first test was random, and there was a 30 minute interval between them.

Intervention% of hemoglobin (Mean)
Healthy Young Subjects95.8
Healthy Elderly Subjects94.9
COPD Patients90.3

"Third Six Minute Walk Test Distance"

"This test will be conducted by the Rater 2, the subject will walk as far as it can in a 30m corridor during 6 minutes. The performance will be the distance (meters)that it walk." (NCT01298661)
Timeframe: On the third day of evaluation, seven days after the first day of evaluation. Since it was performed in the same day of the third 6MST, the choice of the first test was random, and there was a 30 minute interval between them.

Interventionmeter (Mean)
Healthy Young Subjects648.3
Healthy Elderly Subjects502
COPD Patients392.4

"Third Six Minute Walk Test Exertion Perception"

"This test will be conducted by the Rater 2, the subject will walk as far as it can in a 30m corridor during 6 minutes. The Exertion Perception will be evaluated using BORG scale. This scale is a self-reported scale, which range from 0 to 10, where 0 means none exertion perception and 10 means very intense exertion perception (the highest the patient has ever felt). Lower values means that the patient feel less discomfort." (NCT01298661)
Timeframe: On the third day of evaluation, seven days after the first day of evaluation. Since it was performed in the same day of the third 6MST, the choice of the first test was random, and there was a 30 minute interval between them.

Interventionunits on a scale (Median)
Healthy Young Subjects1
Healthy Elderly Subjects1
COPD Patients2

"Third Six Minute Walk Test Heart Rate"

"This test will be conducted by the Rater 2, the subject will walk as far as it can in a 30m corridor during 6 minutes. It will be evaluated by a cardio monitor." (NCT01298661)
Timeframe: On the third day of evaluation, seven days after the first day of evaluation. Since it was performed in the same day of the third 6MST, the choice of the first test was random, and there was a 30 minute interval between them.

Interventionbpm (Mean)
Healthy Young Subjects145
Healthy Elderly Subjects112
COPD Patients114

"Third Six Minute Walk Test Peripheral Oxygen Saturation"

"This test will be conducted by the Rater 2, the subject will walk as far as it can in a 30m corridor during 6 minutes. It will be evaluated by a pulse oxymeter." (NCT01298661)
Timeframe: On the third day of evaluation, seven days after the first day of evaluation. Since it was performed in the same day of the third 6MST, the choice of the first test was random, and there was a 30 minute interval between them.

Intervention% of hemoglobin (Mean)
Healthy Young Subjects96.1
Healthy Elderly Subjects94.7
COPD Patients89.7

Reviews

6 reviews available for carbon monoxide and Diffuse Parenchymal Lung Disease

ArticleYear
Predictors of progression in systemic sclerosis patients with interstitial lung disease.
    The European respiratory journal, 2020, Volume: 55, Issue:5

    Topics: Biomarkers; Carbon Monoxide; Disease Progression; Humans; Lung; Lung Diseases, Interstitial; Respira

2020
Office-based DLCO tests help pulmonologists to make important clinical decisions.
    Respiratory investigation, 2016, Volume: 54, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Female; Follow-Up Studies; Humans; Lung Diseases, I

2016
Diffusing capacity.
    Clinical reviews in allergy & immunology, 2009, Volume: 37, Issue:3

    Topics: Carbon Monoxide; Diffusion; Evaluation Studies as Topic; Humans; Lung; Lung Diseases, Interstitial;

2009
[Early diagnosis of connective tissue disease-related pulmonary hypertension].
    Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 2009, Volume: 32, Issue:6

    Topics: Biomarkers; Carbon Monoxide; Chronic Disease; Connective Tissue Diseases; Early Diagnosis; Echocardi

2009
Pulmonary physiology in interstitial lung disease: recent developments in diagnostic and prognostic implications.
    Current opinion in pulmonary medicine, 1996, Volume: 2, Issue:5

    Topics: Airway Resistance; Biopsy; Bronchoalveolar Lavage Fluid; Carbon Monoxide; Female; Forced Expiratory

1996
Pulmonary involvement in Niemann-Pick disease: case report and literature review.
    Respiratory medicine, 2000, Volume: 94, Issue:12

    Topics: Carbon Monoxide; Diffusion; Female; Humans; Lung Diseases, Interstitial; Middle Aged; Niemann-Pick D

2000

Trials

3 trials available for carbon monoxide and Diffuse Parenchymal Lung Disease

ArticleYear
Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.
    Annals of the rheumatic diseases, 2019, Volume: 78, Issue:1

    Topics: Adult; Carbon Monoxide; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female;

2019
Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.
    Annals of the rheumatic diseases, 2016, Volume: 75, Issue:2

    Topics: Adult; Carbon Monoxide; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Multivariate

2016
Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.
    Annals of the rheumatic diseases, 2016, Volume: 75, Issue:2

    Topics: Adult; Carbon Monoxide; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Multivariate

2016
Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.
    Annals of the rheumatic diseases, 2016, Volume: 75, Issue:2

    Topics: Adult; Carbon Monoxide; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Multivariate

2016
Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.
    Annals of the rheumatic diseases, 2016, Volume: 75, Issue:2

    Topics: Adult; Carbon Monoxide; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Multivariate

2016
High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
    International journal of rheumatic diseases, 2009, Volume: 12, Issue:3

    Topics: Adult; Carbon Monoxide; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Glucocorticoids;

2009

Other Studies

71 other studies available for carbon monoxide and Diffuse Parenchymal Lung Disease

ArticleYear
Risk Factors Associated with Impairment in Pulmonary Diffusing Capacity among Patients with Noncystic Fibrosis Bronchiectasis.
    Canadian respiratory journal, 2022, Volume: 2022

    Topics: Bronchiectasis; Carbon Monoxide; Fibrosis; Humans; Lung Diseases, Interstitial; Pulmonary Diffusing

2022
Anti-vinculin antibodies as a novel biomarker in Egyptian patients with systemic sclerosis.
    Clinical rheumatology, 2022, Volume: 41, Issue:11

    Topics: Autoantibodies; Biomarkers; Carbon Monoxide; Egypt; Female; Humans; Lung Diseases, Interstitial; Mal

2022
Interstitial lung disease in patients with systemic lupus erythematosus: a cohort study.
    Turkish journal of medical sciences, 2022, Volume: 52, Issue:1

    Topics: Carbon Monoxide; Cohort Studies; Humans; Hydroxychloroquine; Lung; Lung Diseases, Interstitial; Lupu

2022
Association Between Interstitial Lung Disease and Outcomes After Lung Cancer Resection.
    The Annals of thoracic surgery, 2023, Volume: 116, Issue:3

    Topics: Carbon Monoxide; Carcinoma, Non-Small-Cell Lung; Humans; Lung; Lung Diseases, Interstitial; Lung Neo

2023
[Rebreathing method for measuring CO transfer factor in children].
    Revue des maladies respiratoires, 2019, Volume: 36, Issue:8

    Topics: Adolescent; Carbon Monoxide; Case-Control Studies; Child; Child, Preschool; Female; Humans; Lung Dis

2019
Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience.
    Lung, 2019, Volume: 197, Issue:6

    Topics: Adult; Age Distribution; Age Factors; Aged; Arthritis, Rheumatoid; Autoimmune Diseases; Carbon Monox

2019
Lung function is associated with minimal EQ-5D changes over time in patients with systemic sclerosis.
    Clinical rheumatology, 2020, Volume: 39, Issue:5

    Topics: Adult; Aged; Carbon Monoxide; Female; Humans; Lung; Lung Diseases, Interstitial; Male; Middle Aged;

2020
Beneficial impact of weight loss on respiratory function in interstitial lung disease patients with obesity.
    Respiratory investigation, 2021, Volume: 59, Issue:2

    Topics: Adult; Aged; Body Mass Index; Carbon Monoxide; Female; Follow-Up Studies; Functional Residual Capaci

2021
Increased Levels of Soluble CD206 Associated with Rapidly Progressive Interstitial Lung Disease in Patients with Dermatomyositis.
    Mediators of inflammation, 2020, Volume: 2020

    Topics: Adult; Autoantibodies; Biomarkers; Carbon Monoxide; Case-Control Studies; Dermatomyositis; Diffusion

2020
Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study.
    Scientific reports, 2021, 01-07, Volume: 11, Issue:1

    Topics: Adult; Aged; C-Reactive Protein; Carbon Monoxide; Case-Control Studies; Cross-Sectional Studies; Cyc

2021
Assessing the applicability of the new Global Lung Function Initiative reference values for the diffusing capacity of the lung for carbon monoxide in a large population set.
    PloS one, 2021, Volume: 16, Issue:1

    Topics: Adult; Aged; Asthma; Bronchitis; Carbon Monoxide; Cystic Fibrosis; Female; Humans; Lung; Lung Diseas

2021
The effects of carbon monoxide releasing molecules on paraquat-induced pulmonary interstitial inflammation and fibrosis.
    Toxicology, 2021, 05-30, Volume: 456

    Topics: Animals; Boranes; Carbon Monoxide; Carbonates; Cell Line; Cell Survival; Dose-Response Relationship,

2021
Performance of Lung Ultrasound for Monitoring Interstitial Lung Disease.
    Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine, 2022, Volume: 41, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Female; Humans; Lung; Lung Diseases, Interstitial;

2022
Cardiopulmonary exercise factors predict survival in patients with advanced interstitial lung disease referred for lung transplantation.
    Respiratory medicine, 2017, Volume: 126

    Topics: Aged; Carbon Monoxide; Cross-Sectional Studies; Exercise Test; Exercise Tolerance; Female; Humans; L

2017
Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease.
    Respiratory medicine, 2017, Volume: 127

    Topics: Aged; Arthritis, Rheumatoid; Carbon Monoxide; Cohort Studies; Dyspnea; Female; Forced Expiratory Vol

2017
The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.
    Respiratory medicine, 2017, Volume: 127

    Topics: Aged; Arthritis, Rheumatoid; Carbon Monoxide; Female; Health Status Indicators; Humans; Idiopathic P

2017
Novel Assessment of Interstitial Lung Disease Using the "Computer-Aided Lung Informatics for Pathology Evaluation and Rating" (CALIPER) Software System in Idiopathic Inflammatory Myopathies.
    Lung, 2017, Volume: 195, Issue:5

    Topics: Adult; Aged; Carbon Monoxide; Cohort Studies; Female; Humans; Image Processing, Computer-Assisted; I

2017
Correlation of pulmonary function and usual interstitial pneumonia computed tomography patterns in idiopathic pulmonary fibrosis.
    Respiratory medicine, 2017, Volume: 129

    Topics: Aged; Aged, 80 and over; Carbon Monoxide; Disease Progression; Female; Humans; Idiopathic Pulmonary

2017
Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease.
    PloS one, 2017, Volume: 12, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carbon Monoxide; Cyclophosphamide; Diffusion; Echocardio

2017
Exertional hypoxemia is more severe in fibrotic interstitial lung disease than in COPD.
    Respirology (Carlton, Vic.), 2018, Volume: 23, Issue:4

    Topics: Aged; Carbon Monoxide; Exercise Test; Female; Humans; Hypoxia; Lung Diseases, Interstitial; Male; Mi

2018
Unclassifiable-interstitial lung disease: Outcome prediction using CT and functional indices.
    Respiratory medicine, 2017, Volume: 130

    Topics: Aged; Bronchiectasis; Carbon Monoxide; Connective Tissue Diseases; Female; Forced Expiratory Volume;

2017
Thin-section computed tomography-determined usual interstitial pneumonia pattern affects the decision-making process for resection in newly diagnosed lung cancer patients: a retrospective study.
    BMC pulmonary medicine, 2018, Jan-05, Volume: 18, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Clinical Decision-Making; Female; Humans; Lung Dise

2018
Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy?
    BMC pulmonary medicine, 2018, Jan-30, Volume: 18, Issue:1

    Topics: Aged; Carbon Monoxide; Female; Forced Expiratory Volume; Humans; Lung; Lung Diseases, Interstitial;

2018
Physiological predictors of Hypoxic Challenge Testing (HCT) outcomes in Interstitial Lung Disease (ILD).
    Respiratory medicine, 2018, Volume: 135

    Topics: Aerospace Medicine; Aged; Aircraft; Algorithms; Carbon Monoxide; Female; Humans; Hypoxia; Idiopathic

2018
Nailfold Videocapillaroscopy Changes Are Associated With the Presence and Severity of Systemic Sclerosis-Related Interstitial Lung Disease.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2019, Volume: 25, Issue:3

    Topics: Adult; Aged; Capillaries; Carbon Monoxide; Female; Humans; Lung Diseases, Interstitial; Male; Micros

2019
Rising stars of DPLD survival: FVC and exercise desaturation (a single-center study)
    Turkish journal of medical sciences, 2018, Aug-16, Volume: 48, Issue:4

    Topics: Age Factors; Aged; Blood Pressure; Carbon Monoxide; Connective Tissue Diseases; Exercise; Exercise T

2018
Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide.
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2019, Volume: 38, Issue:2

    Topics: Aged; Carbon Monoxide; Chronic Disease; Female; Follow-Up Studies; Forced Expiratory Volume; Humans;

2019
Comparison of clinical courses and mortality of connective tissue disease-associated interstitial pneumonias and chronic fibrosing idiopathic interstitial pneumonias.
    The Kaohsiung journal of medical sciences, 2019, Volume: 35, Issue:6

    Topics: Aged; Carbon Monoxide; Disease Progression; Female; Forced Expiratory Volume; Humans; Idiopathic Int

2019
Clinical significance of autoantibody positivity in idiopathic pulmonary fibrosis.
    Respiratory medicine, 2019, Volume: 155

    Topics: Aged; Antibodies, Antineutrophil Cytoplasmic; Autoantibodies; Carbon Monoxide; Female; Glucocorticoi

2019
Comparison of different measures of diffusing capacity for carbon monoxide (DLCO) in systemic sclerosis.
    Clinical rheumatology, 2013, Volume: 32, Issue:10

    Topics: Aged; Carbon Monoxide; Cohort Studies; Female; Humans; Hypertension, Pulmonary; Lung; Lung Diseases,

2013
Predictors of exercise-induced oxygen desaturation in systemic sclerosis patients with interstitial lung disease.
    Respiratory care, 2014, Volume: 59, Issue:1

    Topics: Aged; Area Under Curve; Carbon Monoxide; Exercise Test; Female; Forced Expiratory Volume; Humans; Lu

2014
Relevance of partitioning DLCO to detect pulmonary hypertension in systemic sclerosis.
    PloS one, 2013, Volume: 8, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Female; Humans; Hypertension, Pulmonary; Lung Disea

2013
[Single-breath and rebreathing methods for measurement of pulmonary diffusing function: a comparative study].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2013, Volume: 36, Issue:7

    Topics: Adult; Aged; Carbon Monoxide; Female; Humans; Lung; Lung Diseases, Interstitial; Male; Middle Aged;

2013
Prevalence and evolution of scleroderma pattern at nailfold videocapillaroscopy in systemic sclerosis patients: Clinical and prognostic implications.
    Microvascular research, 2015, Volume: 99

    Topics: Adult; Aged; Autoantibodies; Capillaries; Carbon Monoxide; Diffusion; Female; Fingers; Follow-Up Stu

2015
Different KCO and VA combinations exist for the same DLCO value in patients with diffuse parenchymal lung diseases.
    BMC pulmonary medicine, 2015, Sep-03, Volume: 15

    Topics: Aged; Airway Obstruction; Carbon Monoxide; Cross-Sectional Studies; Female; Humans; Lung; Lung Disea

2015
Diffusing Pulmonary Capacity Measured During Effort: A Possible Early Marker of Pulmonary Involvement In Systemic Sclerosis.
    The Israel Medical Association journal : IMAJ, 2015, Volume: 17, Issue:12

    Topics: Biomarkers; Carbon Monoxide; Case-Control Studies; Exercise Test; Female; Humans; Lung Diseases, Int

2015
Elevated Erythrocyte Sedimentation Rate Is Predictive of Interstitial Lung Disease and Mortality in Dermatomyositis: a Korean Retrospective Cohort Study.
    Journal of Korean medical science, 2016, Volume: 31, Issue:3

    Topics: Adult; Asian People; Blood Sedimentation; Carbon Monoxide; Cohort Studies; Dermatomyositis; Disease

2016
Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline.
    Reumatismo, 2015, Dec-23, Volume: 67, Issue:4

    Topics: Adult; Aged; Antibodies, Antinuclear; Autoantibodies; Biomarkers; Carbon Monoxide; Female; Follow-Up

2015
Pseudoxanthoma Elasticum - Also a Lung Disease? The Respiratory Affection of Patients with Pseudoxanthoma Elasticum.
    PloS one, 2016, Volume: 11, Issue:9

    Topics: Adult; Aged; Carbon Monoxide; Case-Control Studies; Cross-Sectional Studies; Female; Forced Expirato

2016
Clinical features and natural history of interstitial pneumonia with autoimmune features: A single center experience.
    Respiratory medicine, 2016, Volume: 119

    Topics: Adrenal Cortex Hormones; Adult; Amino Acyl-tRNA Synthetases; Antibodies, Antinuclear; Autoimmune Dis

2016
Clinical characteristics in patients with asymmetric idiopathic pulmonary fibrosis.
    Respiratory medicine, 2016, Volume: 119

    Topics: Aged; Biopsy; Carbon Monoxide; Case-Control Studies; Disease Progression; Female; Forced Expiratory

2016
Prognostic determinants among clinical, thin-section CT, and histopathologic findings for fibrotic idiopathic interstitial pneumonias: tertiary hospital study.
    Radiology, 2008, Volume: 249, Issue:1

    Topics: Bronchoalveolar Lavage Fluid; Carbon Monoxide; Female; Fibrosis; Humans; Lung Diseases, Interstitial

2008
T-cell activation profiles in different granulomatous interstitial lung diseases--a role for CD8+CD28(null) cells?
    Clinical and experimental immunology, 2010, Volume: 160, Issue:2

    Topics: Adrenal Cortex Hormones; Adult; Aged; Alveolitis, Extrinsic Allergic; Antigens, CD; Bronchoalveolar

2010
Clinical and high resolution computed tomography characteristics of patients with rheumatoid arthritis lung disease.
    International journal of rheumatic diseases, 2009, Volume: 12, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Asian People; Bronchiectasis; Carbon Monoxide

2009
Impaired lung compliance and DL,CO but no restrictive ventilatory defect in sarcoidosis.
    The European respiratory journal, 2010, Volume: 36, Issue:6

    Topics: Adult; Carbon Monoxide; Female; Humans; Lung; Lung Compliance; Lung Diseases, Interstitial; Male; Mi

2010
MRP14 is elevated in the bronchoalveolar lavage fluid of fibrosing interstitial lung diseases.
    Clinical and experimental immunology, 2010, Volume: 161, Issue:2

    Topics: Adult; Aged; Biomarkers; Bronchoalveolar Lavage Fluid; Calgranulin B; Carbon Monoxide; Cell Count; F

2010
Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.
    Chest, 2011, Volume: 140, Issue:4

    Topics: Adult; Aged; Antibodies, Antinuclear; Blood Pressure; Carbon Monoxide; Comorbidity; Cross-Sectional

2011
Impaired carbon monoxide diffusing capacity as a marker of limited systemic sclerosis.
    European journal of internal medicine, 2011, Volume: 22, Issue:6

    Topics: Adult; Aged; Biomarkers; Carbon Monoxide; Diagnosis, Differential; Diffusion; Female; Follow-Up Stud

2011
Clinical significance of serum levels of secretory leukocyte protease inhibitor in patients with systemic sclerosis.
    Modern rheumatology, 2012, Volume: 22, Issue:4

    Topics: Biomarkers; Carbon Monoxide; Enzyme-Linked Immunosorbent Assay; Female; Humans; Lung; Lung Diseases,

2012
Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy.
    The European respiratory journal, 2012, Volume: 40, Issue:3

    Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Carbon Monoxide; Connective Tissue Diseases; Female;

2012
Detection of interstitial lung disease in systemic sclerosis through partitioning of lung transfer for carbon monoxide.
    Respiration; international review of thoracic diseases, 2012, Volume: 84, Issue:6

    Topics: Adult; Aged; Blood Volume; Breath Tests; Capillaries; Carbon Monoxide; Case-Control Studies; Female;

2012
The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis.
    Chest, 2012, Volume: 142, Issue:6

    Topics: Adult; Aged; Carbon Monoxide; Case-Control Studies; Female; Genetic Predisposition to Disease; Genot

2012
Respiratory muscle function in interstitial lung disease.
    The European respiratory journal, 2013, Volume: 42, Issue:1

    Topics: Aged; Anthropometry; Biomarkers; Carbon Monoxide; Case-Control Studies; Diaphragm; Exercise Test; Fe

2013
An infant with pulmonary interstitial glycogenosis: clinical improvement is associated with improvement in the pulmonary diffusion capacity.
    Pediatric pulmonology, 2014, Volume: 49, Issue:3

    Topics: Breath Tests; Carbon Monoxide; Disease Progression; Forced Expiratory Volume; Glucocorticoids; Glyco

2014
Effect of hypobaric hypoxia on blood gases in patients with restrictive lung disease.
    The European respiratory journal, 2002, Volume: 20, Issue:2

    Topics: Adult; Aged; Atmospheric Pressure; Blood Gas Analysis; Carbon Dioxide; Carbon Monoxide; Chronic Dise

2002
Diagnosis of interstitial lung disease in patients with connective tissue disease by the diffusing capacity of carbon monoxide.
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2002, Volume: 25, Issue:7

    Topics: Carbon Monoxide; Connective Tissue Diseases; Humans; Lung Diseases, Interstitial; Radiography, Thora

2002
Pulmonary side effects of interferon-alpha therapy in patients with hematological malignancies.
    American journal of hematology, 2003, Volume: 73, Issue:1

    Topics: Adult; Aged; Autoimmunity; Carbon Monoxide; Female; Hematologic Neoplasms; Humans; Immunity, Cellula

2003
Pulmonary involvement in type 1 Gaucher disease: functional and exercise findings in patients with and without clinical interstitial lung disease.
    Clinical genetics, 2003, Volume: 63, Issue:5

    Topics: Adolescent; Adult; Biopsy; Carbon Monoxide; Citrates; Exercise; Exercise Test; Female; Gallium; Gauc

2003
Adult-onset familial pulmonary fibrosis in Japanese brothers.
    Pathology international, 2004, Volume: 54, Issue:1

    Topics: Adult; Carbon Monoxide; Consanguinity; DNA Mutational Analysis; Fatal Outcome; Female; Genetic Predi

2004
Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001.
    Rheumatology (Oxford, England), 2005, Volume: 44, Issue:3

    Topics: Age Factors; Blood Pressure; Calcitonin Gene-Related Peptide; Carbon Monoxide; Echocardiography, Dop

2005
High plasma concentrations of osteopontin in patients with interstitial pneumonia.
    Respiratory medicine, 2005, Volume: 99, Issue:1

    Topics: Adult; Aged; Biomarkers; Carbon Monoxide; Female; Humans; Immunoenzyme Techniques; Lung Diseases, In

2005
Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation.
    Respiratory medicine, 2005, Volume: 99, Issue:11

    Topics: Adult; Carbon Monoxide; Cohort Studies; Exercise Test; Female; Humans; Lung Diseases, Interstitial;

2005
Diffusing capacity for nitric oxide and carbon monoxide in patients with diffuse parenchymal lung disease and pulmonary arterial hypertension.
    Chest, 2006, Volume: 129, Issue:2

    Topics: Adult; Carbon Monoxide; Female; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Male;

2006
Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: implications for the diagnosis of combined obstructive and restrictive lung disease.
    Mayo Clinic proceedings, 2007, Volume: 82, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Dyspnea; Echocardiography; Female; Humans; Lung Dis

2007
Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide.
    The European respiratory journal, 2007, Volume: 30, Issue:1

    Topics: Aged; Carbon Monoxide; Echocardiography; Female; Fibrosis; Humans; Lung Diseases; Lung Diseases, Int

2007
Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease.
    The Journal of rheumatology, 2007, Volume: 34, Issue:5

    Topics: Adult; Carbon Monoxide; Comorbidity; Dyspnea; Female; Humans; Hypertension, Pulmonary; Lung Diseases

2007
[Lung involvement in systemic sclerosis].
    Medicina, 2007, Volume: 67, Issue:5

    Topics: Adolescent; Adult; Aged; Biomarkers; Carbon Monoxide; Child; DNA Topoisomerases, Type I; Female; Hum

2007
Discrete lung involvement in systemic lupus erythematosus: CT assessment.
    Radiology, 1995, Volume: 196, Issue:3

    Topics: Adult; Bronchial Diseases; Carbon Monoxide; Female; Forced Expiratory Volume; Humans; Lung Diseases;

1995
[Diagnostic value of exercise diffusion capacity test on diffuse pulmonary fibrosis].
    Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao, 1996, Volume: 27, Issue:2

    Topics: Adult; Carbon Monoxide; Exercise Test; Female; Humans; Lung; Lung Diseases, Interstitial; Lung Disea

1996
Serum KL-6 as a possible marker for amiodarone-induced pulmonary toxicity.
    Internal medicine (Tokyo, Japan), 2000, Volume: 39, Issue:12

    Topics: Amiodarone; Anti-Arrhythmia Agents; Antigens; Antigens, Neoplasm; Biomarkers; Carbon Monoxide; Cardi

2000
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
    Chest, 2001, Volume: 120, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun

2001
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
    Chest, 2001, Volume: 120, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun

2001
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
    Chest, 2001, Volume: 120, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun

2001
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
    Chest, 2001, Volume: 120, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun

2001
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
    Chest, 2001, Volume: 120, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun

2001
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
    Chest, 2001, Volume: 120, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun

2001
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
    Chest, 2001, Volume: 120, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun

2001
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
    Chest, 2001, Volume: 120, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun

2001
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
    Chest, 2001, Volume: 120, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun

2001